Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer and Bristol-Myers Squibb granted EU approval for Eliquis

Pfizer and Bristol-Myers Squibb granted EU approval for Eliquis

23rd May 2011

Pfizer and Bristol-Myers Squibb have been granted European marketing clearance for Eliquis, their new treatment for venous thromboembolic events among orthopaedic surgery patients.

The partners have received their first regulatory approval for the drug from the European Commission, which based its decision on positive data from the Advance-2 and Advance-3 clinical trials.

Eliquis is an oral direct Factor Xa inhibitor designed for patients that have undergone elective hip or knee replacement surgery and who are at a high risk of suffering pulmonary embolisms or deep vein thrombosis.

This represents a major milestone for the alliance between the two companies, which has been ongoing since 2007 and combines both organisations' respective expertise.

Olivier Brandicourt, president and general manager for primary care at Pfizer, said: "The approval of Eliquis provides a new oral option for patients in the EU undergoing elective hip or knee replacement surgery, where the risk of bleeding is a significant concern."

Last week, Pfizer announced positive clinical trial data from a phase III study of axitinib, a new therapy for advanced renal cell carcinoma.ADNFCR-8000103-ID-800552664-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.